1. Use of erythropoietin for preparing a pharmaceutical preparation intended to enhance survival of fat cells implanted in need thereof subekta.2. Use of erythropoietin for preparing a pharmaceutical preparation intended to enhance survival of fat kletok.3. Use of erythropoietin for the manufacture of a medicament for the treatment of soft tkaney.4 defect. Use according to claim 1, 2 or 3, carried out ex vivo.5. Use according to claim 1, 2 or 3, carried out in vivo.6. Use according to claim 3, wherein said soft tissue defect is selected from the group consisting of skin, skin disorders, wounds, burns, cancer, surgery, reconstructive surgery, skin depressions, congenital and acquired zabolevaniya.7. Use according to claim 1, 2 or 3, wherein said erythropoietin is administered directly into said body kletki.8. Use according to claim 7, wherein the dosage of said erythropoietin is approximately 1-1000 ME per injection on Body kletok.9 1,000,000. Use according to claim 1, 2 or 3, prepared for systemic vvedeniya.10. Use according to claim 9, wherein said erythropoietin dose is about 10-7500 ME tela.11 1 kg weight. Use according to claim 1, 2 or 3, further comprising at least one factor selected from the group consisting of an extracellular matrix component, a growth factor, a hormone, an angiogenic factor, clotting factor, cytokine, chemokine, enzyme, neurotransmitter, vitamin, carbohydrate , ion, an iron chelator, a fatty acid, an antibiotic and aminokisloty.12. Use according to claim 1, 2 or 31. Применение эритропоэтина для получения лекарственного препарата, предназначенного для повышения выживаемости имплантированных жировых клеток у нуждающегося в этом субъекта.2. Применение эритропоэтина для получения лекарственного препарата, предназначенного для повышения выживаемости жировых клеток.3. Применение эритропоэтина для получения лекарственного препарата, предназначенного для лечения дефекта мягких тканей.4. Применение по пп.1, 2 или 3, осуществляемое ex vivo.5. Примен
